Perspective Therapeutics (NYSE:CATX) versus Todos Medical (OTCMKTS:TOMDF) Head-To-Head Survey

Perspective Therapeutics (NYSE:CATX) and Todos Medical (OTCMKTS:TOMDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Perspective Therapeutics and Todos Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	9	0	3.00
Todos Medical	0	0	0	0	0.00

Perspective Therapeutics presently has a consensus target price of $21.57, indicating a potential upside of 218.16%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Perspective Therapeutics is more favorable than Todos Medical.

Volatility & Risk

Perspective Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Todos Medical has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.

Profitability

This table compares Perspective Therapeutics and Todos Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Todos Medical	N/A	N/A	N/A

Earnings & Valuation

This table compares Perspective Therapeutics and Todos Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43 million	320.46	-$46.51 million	N/A	N/A
Todos Medical	$12.23 million	0.02	-$43.31 million	N/A	N/A

Todos Medical has higher revenue and earnings than Perspective Therapeutics.

Summary

Perspective Therapeutics beats Todos Medical on 7 of the 12 factors compared between the two stocks.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About Todos Medical

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.